Pipeline
Our 1st development strategy focuses on chronic respiratory diseases where bacterial biofilms play a critical role in disease progression and recurrent exacerbations.
Current Focus and Future Opportunities
Hermione Therapeutics prioritizes the development of inhaled ANP for COPD and bronchiectasis associated with P. aeruginosa, where bacterial biofilms contribute to recurrent exacerbations and limited treatment options.
Other respiratory indications of interest with inhaled ANP
The anti-biofilm mechanism of inhaled ANP may also be relevant in other respiratory diseases where persistent biofilm-associated infections remain an important therapeutic challenge.
Ventilator-Associated Pneumonia
P. aeruginosa is a leading cause of ventilator-associated pneumonia in intensive care units, where biofilm-associated infections remain difficult to treat.
Cystic Fibrosis
Chronic P. aeruginosa colonization affects the majority of adult cystic fibrosis patients, driving persistent infections despite antibiotic therapy.
COPD
bronchiectasis
Advancing ANP Toward Clinical Development
Since the discovery of ANP’s anti-biofilm properties, significant progress has been made across research, intellectual property protection and preclinical validation. Hermione Therapeutics is now advancing ANP through the key milestones required to enter clinical development.
Advancing a New Approach to Respiratory Infections
Discover the preclinical data supporting Hermione’s anti-biofilm platform.
